

Sharyn D Baker

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8646935/sharyn-d-baker-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

198 papers	9,557 citations	58 h-index	91 g-index
210 ext. papers	10,533 ext. citations	6.2 avg, IF	5.41 L-index

#	Paper	IF	Citations
198	The genomic landscape of hypodiploid acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2013 , 45, 242-52	36.3	474
197	CREBBP mutations in relapsed acute lymphoblastic leukaemia. <i>Nature</i> , 2011 , 471, 235-9	50.4	468
196	Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. <i>Clinical Cancer Research</i> , 2007 , 13, 3731-7	12.9	237
195	An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. <i>Cancer Research</i> , 2004 , 64, 9139-43	10.1	224
194	Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 1739-42	9.7	218
193	Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 1883-8	9.7	211
192	Interaction of imatinib with human organic ion carriers. <i>Clinical Cancer Research</i> , 2008 , 14, 3141-8	12.9	176
191	Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. <i>Molecular Cancer Therapeutics</i> , 2002 , 1, 545-52	6.1	170
190	Irinotecan pathway genotype analysis to predict pharmacokinetics. <i>Clinical Cancer Research</i> , 2003 , 9, 3246-53	12.9	164
189	Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. <i>Cancer Biology and Therapy</i> , 2007 , 6, 432-8	4.6	159
188	A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 44, 372-80	3.5	147
187	Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. <i>Blood</i> , 2013 , 122, 3607-15	2.2	140
186	Pharmacogenetic pathway analysis of docetaxel elimination. <i>Clinical Pharmacology and Therapeutics</i> , 2009 , 85, 155-63	6.1	135
185	Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. <i>Clinical Cancer Research</i> , 2009 , 15, 6062-9	12.9	132
184	Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. <i>Journal of Clinical Oncology</i> , 1996 , 14, 3074-84	2.2	126
183	Clinical pharmacokinetics of docetaxel : recent developments. <i>Clinical Pharmacokinetics</i> , 2006 , 45, 235-52	5.2	125
182	Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3293-300	2.2	124

181	Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4707-13	2.2	123
180	Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. <i>Journal of Clinical Oncology</i> , 1996 , 14, 3085-96	2.2	117
179	Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015 , 28, 343-56	24.3	114
178	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. <i>Clinical Cancer Research</i> , 2013 , 19, 1458-66	12.9	109
177	Factors affecting cytochrome P-450 3A activity in cancer patients. <i>Clinical Cancer Research</i> , 2004 , 10, 8341-50	12.9	107
176	Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 192-201	6.1	105
175	Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1996 , 37, 195-202	3.5	105
174	Pharmacology of Cancer Chemotherapy in the Older Person. <i>Clinics in Geriatric Medicine</i> , 1997 , 13, 169-183	3.3	103
173	Effect of milk thistle (<i>Silybum marianum</i>) on the pharmacokinetics of irinotecan. <i>Clinical Cancer Research</i> , 2005 , 11, 7800-6	12.9	102
172	Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2604-13	2.2	101
171	Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. <i>Clinical Cancer Research</i> , 2004 , 10, 1976-83	12.9	98
170	Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5504-10	2.2	94
169	Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, 448-54	6.1	94
168	CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 1714-23	9.7	93
167	Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1070-7	2.2	92
166	Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. <i>Journal of Clinical Oncology</i> , 2001 , 19, 762-71	2.2	91
165	Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. <i>Clinical Cancer Research</i> , 2007 , 13, 7394-400	12.9	88
164	Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. <i>Clinical Cancer Research</i> , 2007 , 13, 2488-95	12.9	88

163	Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3906-11	2.2	88
162	Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. <i>Journal of Clinical Oncology</i> , 2006 , 24, 552-62	2.2	86
161	A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. <i>Leukemia</i> , 2010 , 24, 1437-44	10.7	82
160	Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 74, 364-71	6.1	81
159	Tumor targeting by conjugation of DHA to paclitaxel. <i>Journal of Controlled Release</i> , 2001 , 74, 233-6	11.7	78
158	Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. <i>Journal of Clinical Oncology</i> , 1994 , 12, 1946-54	2.2	77
157	A phosphotyrosine switch regulates organic cation transporters. <i>Nature Communications</i> , 2016 , 7, 10880	17.4	74
156	Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. <i>Clinical Cancer Research</i> , 2013 , 19, 5758-68	12.9	74
155	Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4562-7	2.2	73
154	Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. <i>Clinical Cancer Research</i> , 2012 , 18, 4433-40	12.9	70
153	Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. <i>Neuro-Oncology</i> , 2005 , 7, 177-82	1	70
152	Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. <i>Journal of Clinical Oncology</i> , 2002 , 20, 656-64	2.2	69
151	A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. <i>Clinical Cancer Research</i> , 2009 , 15, 6241-9	12.9	68
150	Relationship of systemic exposure to unbound docetaxel and neutropenia. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 77, 43-53	6.1	68
149	Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. <i>Clinical Cancer Research</i> , 2013 , 19, 3050-8	12.9	67
148	Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry. <i>Analytical Biochemistry</i> , 2004 , 324, 276-84	3.1	67
147	Pharmacokinetics and toxicity of weekly docetaxel in older patients. <i>Clinical Cancer Research</i> , 2006 , 12, 6100-5	12.9	65
146	Ductal access for prevention and therapy of mammary tumors. <i>Cancer Research</i> , 2006 , 66, 638-45	10.1	64

145	Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51. <i>PLoS ONE</i> , 2013 , 8, e79106	3.7	63
144	Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. <i>Nature Communications</i> , 2019 , 10, 244	17.4	63
143	Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. <i>Journal of Clinical Oncology</i> , 2000 , 18, 915-26	2.2	62
142	Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. <i>Investigational New Drugs</i> , 2006 , 24, 291-7	4.3	60
141	Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. <i>Clinical Cancer Research</i> , 2005 , 11, 7398-404	12.9	60
140	Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4172-9	2.2	58
139	Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1095-104	2.2	57
138	Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. <i>Journal of Clinical Oncology</i> , 1996 , 14, 1504-11	2.2	57
137	Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. <i>Clinical Cancer Research</i> , 2013 , 19, 236-46	12.9	56
136	Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003 , 793, 413-20	3.2	55
135	Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. <i>Clinical Cancer Research</i> , 2003 , 9, 3589-97	12.9	54
134	Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008 , 874, 84-8	3.2	52
133	Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005 , 819, 73-80	3.2	52
132	Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. <i>British Journal of Cancer</i> , 2012 , 107, 1100-6	8.7	50
131	Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4986-93	2.2	50
130	Population pharmacokinetic model for topotecan derived from phase I clinical trials. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2459-67	2.2	50
129	A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. <i>Clinical Cancer Research</i> , 2005 , 11, 664-71	12.9	48
128	A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators Consortium study (POE 10-03). <i>Pediatric Blood and Cancer</i> , 2017 , 61, e26114	3	46

127	Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b. <i>Cancer Research</i> , 2015 , 75, 2729-36	10.1	46
126	Inhibition of OCTN2-mediated transport of carnitine by etoposide. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 921-9	6.1	46
125	Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2006 , 12, 1270-5	12.9	46
124	Simultaneous determination of steroid composition of human testicular fluid using liquid chromatography tandem mass spectrometry. <i>Steroids</i> , 2004 , 69, 721-6	2.8	46
123	Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). <i>Clinical Cancer Research</i> , 2014 , 20, 985-94	12.9	45
122	Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 893-905	9.7	45
121	Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. <i>Clinical Pharmacology and Therapeutics</i> , 2008 , 84, 704-9	6.1	45
120	Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. <i>Clinical Pharmacology and Therapeutics</i> , 2008 , 83, 477-84	6.1	44
119	Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. <i>Journal of Clinical Oncology</i> , 2000 , 18, 4086-97	2.2	44
118	Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010 , 878, 3033-8	3.2	43
117	A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007 , 846, 1-7	3.2	43
116	Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 1110-20	6.1	40
115	Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements. <i>Clinical Pharmacology and Therapeutics</i> , 2008 , 84, 111-8	6.1	39
114	Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. <i>Clinical Cancer Research</i> , 2003 , 9, 151-9	12.9	39
113	Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. <i>British Journal of Cancer</i> , 2014 , 110, 894-8	8.7	38
112	Marginal increase of sunitinib exposure by grapefruit juice. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 695-703	3.5	36
111	Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy. <i>Cytometry</i> , 1995 , 19, 134-45		35
110	Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib. <i>Clinical Cancer Research</i> , 2013 , 19, 4359-4370	12.9	34

109	Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 274-8	4.7	34
108	Ontogeny and sorafenib metabolism. <i>Clinical Cancer Research</i> , 2012 , 18, 5788-95	12.9	34
107	Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death. <i>Cancer Research</i> , 2016 , 76, 117-26	10.1	33
106	Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004 , 813, 81-8	3.2	33
105	Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 61, 423-33	3.5	32
104	Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002 , 773, 183-90	3.2	32
103	Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies. <i>Journal of Clinical Oncology</i> , 1998 , 16, 2770-9	2.2	31
102	OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. <i>Cancer Research</i> , 2017 , 77, 2102-2111	10.1	30
101	Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 693-701	6.1	30
100	Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 536-42	12.9	30
99	Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. <i>Journal of Clinical Oncology</i> , 2002 , 20, 96-109	2.2	30
98	Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 1039-52	3.5	30
97	Evaluation of artemisinins for the treatment of acute myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 1231-43	3.5	30
96	Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy. <i>Clinical Cancer Research</i> , 2012 , 18, 4425-32	12.9	29
95	Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7765-7	2.2	29
94	Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2959-65	2.2	27
93	Pharmacokinetic considerations for new targeted therapies. <i>Clinical Pharmacology and Therapeutics</i> , 2009 , 85, 208-11	6.1	26
92	Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2018 , 128, 369-380	15.9	25

91	Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study. <i>Pharmacotherapy</i> , 2004 , 24, 16-25	5.8	22
90	OATP1B1 polymorphism as a determinant of erythromycin disposition. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 92, 642-50	6.1	21
89	Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. <i>Pharmacogenomics</i> , 2011 , 12, 327-39	2.6	21
88	Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100. <i>British Journal of Cancer</i> , 2008 , 98, 1630-2	8.7	21
87	A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion. <i>Annals of Oncology</i> , 1998 , 9, 101-4	10.3	21
86	Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthone-4-acetic acid in cancer patients. <i>Clinical Cancer Research</i> , 2008 , 14, 2102-10	12.9	20
85	Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2567-74	2.2	20
84	Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2016 , 99, 651-60	6.1	19
83	Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006 , 29, 395-8	2.7	19
82	Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. <i>Leukemia Research</i> , 2011 , 35, 87-94	2.7	18
81	Pharmacology of fluorinated pyrimidines: eniluracil. <i>Investigational New Drugs</i> , 2000 , 18, 373-81	4.3	18
80	A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies. <i>Investigational New Drugs</i> , 2006 , 24, 499-508	4.3	16
79	Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 227-237	6.1	16
78	Role of Oatp2b1 in Drug Absorption and Drug-Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2020 , 48, 419-425	4	15
77	Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 153-62	4.4	15
76	Determination of fraction unbound docetaxel using microequilibrium dialysis. <i>Analytical Biochemistry</i> , 2004 , 331, 192-194	3.1	15
75	Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models. <i>Cancer Biology and Therapy</i> , 2007 , 6, 891-7	4.6	14
74	Limited cerebrospinal fluid penetration of docetaxel. <i>Anti-Cancer Drugs</i> , 2004 , 15, 715-8	2.4	14

73	A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. <i>Leukemia</i> , 2020 , 34, 735-745	10.7	14
72	Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. <i>Investigational New Drugs</i> , 2020 , 38, 340-349	4.3	13
71	Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 8	22.4	11
70	Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue. <i>Clinical Cancer Research</i> , 2006 , 12, 2158-65	12.9	11
69	Characterization of topotecan-mediated redistribution of DNA topoisomerase I by digital imaging microscopy. <i>Experimental Cell Research</i> , 1998 , 241, 332-9	4.2	11
68	Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. <i>Clinical Cancer Research</i> , 2019 , 25, 7320-7330	12.9	10
67	Stability of sunitinib in oral suspension. <i>Annals of Pharmacotherapy</i> , 2008 , 42, 962-6	2.9	10
66	A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2007 , 43, 784-7	3.5	10
65	Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 74, 509-10	6.1	10
64	Validation and implementation of a method for determination of bryostatin 1 in human plasma by using liquid chromatography/tandem mass spectrometry. <i>Analytical Biochemistry</i> , 2005 , 337, 143-8	3.1	10
63	A kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in epithelial cell death and kidney injury. <i>Nature Communications</i> , 2020 , 11, 1924	17.4	10
62	A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. <i>Nature Communications</i> , 2019 , 10, 2189	17.4	9
61	In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent. <i>Clinical Cancer Research</i> , 2005 , 11, 8503-11	12.9	9
60	Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors. <i>Pharmaceutics</i> , 2020 , 12,	6.4	9
59	Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia. <i>ACS Omega</i> , 2017 , 2, 1985-2009	3.9	8
58	Alternative formulations of sorafenib for use in children. <i>Pediatric Blood and Cancer</i> , 2013 , 60, 1642-6	3	8
57	E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia. <i>Leukemia</i> , 2017 , 31, 502-505	10.7	8
56	Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. <i>Investigational New Drugs</i> , 2011 , 29, 1057-65	4.3	8

55	Distribution of paclitaxel in plasma and cerebrospinal fluid. <i>Anti-Cancer Drugs</i> , 2003 , 14, 365-8	2.4	8
54	Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018 , 1090, 43-51	3.2	8
53	Interaction Between Sex and Organic Anion-Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib-N-Oxide and Regorafenib-Glucuronide in Mice. <i>Clinical and Translational Science</i> , 2019 , 12, 400-407	4.9	7
52	High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study. <i>Annals of Oncology</i> , 1998 , 9, 173-80	10.3	7
51	Targeting OCT3 attenuates doxorubicin-induced cardiac injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	7
50	Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine. <i>Cancer</i> , 2017 , 123, 3602-3608	6.4	6
49	Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma for clinical pharmacology studies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2006 , 42, 253-60	3.5	6
48	TP-0903 is active in models of drug-resistant acute myeloid leukemia. <i>JCI Insight</i> , 2020 , 5,	9.9	6
47	Determination of fraction unbound docetaxel using microequilibrium dialysis. <i>Analytical Biochemistry</i> , 2004 , 331, 192-4	3.1	6
46	Development and validation of a sensitive UHPLC-MS/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020 , 1152, 122176	3.2	6
45	Design, synthesis and evaluation of anti-CD123 antibody drug conjugates. <i>Bioorganic and Medicinal Chemistry</i> , 2016 , 24, 5855-5860	3.4	6
44	Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice. <i>Pharmacology Research and Perspectives</i> , 2019 , 7, e00534	3.1	6
43	DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia. <i>Clinical and Translational Science</i> , 2021 , 14, 137-142	4.9	6
42	Clinical significance of in vivo cytarabine-induced gene expression signature in AML. <i>Leukemia and Lymphoma</i> , 2016 , 57, 909-20	1.9	5
41	Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML. <i>Clinical and Translational Science</i> , 2019 , 12, 641-647	4.9	5
40	Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. <i>Investigational New Drugs</i> , 2007 , 25, 237-45	4.3	5
39	Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation. <i>Leukemia and Lymphoma</i> , 2017 , 58, 247-250	1.9	4
38	A sensitive method for determination of COL-3, a chemically modified tetracycline, in human plasma using high-performance liquid chromatography and ultraviolet detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2005 , 37, 751-6	3.5	4

37	Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021 ,	3.1	4
36	Pharmacokinetic Studies in Early Anticancer Drug Development 2011 , 189-214		3
35	Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies. <i>Annals of Oncology</i> , 2008 , 19, 374-9	10.3	3
34	Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours. <i>European Journal of Cancer</i> , 2007 , 43, 78-86	7.5	3
33	A rapid and sensitive method for determination of dimethyl benzoylphenyl urea in human plasma by using LC/MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2003 , 33, 725-33	3.5	3
32	Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML. <i>Blood</i> , 2015 , 126, 3695-3695	2.2	3
31	Pilot Study of Combined Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib with Sorafenib in Pediatric Patients with Relapsed/Refractory FLT3+Ve AML. <i>Blood</i> , 2016 , 128, 3937-3937	2.2	3
30	A method for determination of dimethyl benzoylphenyl urea (BPU) in human plasma by using LC/UV. <i>Biomedical Chromatography</i> , 2004 , 18, 282-7	1.7	2
29	Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group Study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000 , 23, 609-13	2.7	2
28	Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib. <i>Pharmaceutics</i> , 2020 , 12,	6.4	2
27	Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition. <i>Kidney International</i> , 2021 , 100, 1214-1226	9.9	2
26	Gilteritinib Inhibits Glutamine Uptake and Utilization in -ITD-Positive AML. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 2207-2217	6.1	2
25	Reply to J. Gligorov et al. <i>Journal of Clinical Oncology</i> , 2011 , 29, e456-e457	2.2	1
24	Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate dimethyl benzoylphenylurea (BPU) and its five metabolites in human plasma and urine for clinical pharmacology studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005 , 826, 41-54	3.2	1
23	Troxacitabine in patients with refractory leukemia. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3356; author reply 3356-7	2.2	1
22	Differentiation Therapy for Poor Risk Myeloid Malignancies: Results of a Dose Finding Study of Bryostatins-1 (BRYO) + GM-CSF.. <i>Blood</i> , 2005 , 106, 2792-2792	2.2	1
21	Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia.. <i>Blood</i> , 2010 , 116, 1073-1073	2.2	1
20	Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition.. <i>Cancer Research Communications</i> , 2021 , 1, 79-89		1

19	Hypoxia Reporter Element Assay. <i>Bio-protocol</i> , 2018 , 8,	0.9	1
18	Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia. <i>Blood Advances</i> , 2021 , 5, 5041-5046	7.8	1
17	Gene Expression Patterns Associated with Cytarabine Pharmacology and Outcome in Pediatric Acute Myeloid Leukemia.. <i>Blood</i> , 2009 , 114, 114-114	2.2	1
16	Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS. <i>Blood</i> , 2013 , 122, 2680-2680	2.2	1
15	Development, validation, and application of an LC-MS/MS method for the determination of the AXL/FLT3 inhibitor gilteritinib in mouse plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021 , 1179, 122882	3.2	1
14	High-Dimensional Analysis Identifies Mechanisms of Gilteritinib Resistance in FLT3-Mutated AML. <i>Blood</i> , 2021 , 138, 207-207	2.2	0
13	Chemotherapy in the Pediatric Patient 2009 , 173-207		0
12	Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators. <i>Blood Cancer Discovery</i> , 2021 , 2, 586-599	7	0
11	Pharmacokinetic Modeling 2004 , 129-137		
10	Preclinical Evaluation of Sorafenib in Combination with Cytarabine and Clofarabine in Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2007 , 110, 4202-4202	2.2	
9	Epigenetic Regulation of OCTN1-mediated Cytarabine Transport in Acute Myeloid Leukemia. <i>FASEB Journal</i> , 2019 , 33, 675.2	0.9	
8	Tyrosine Kinase Inhibitor (TKI) Combination Scheduling Impacts Secondary FLT3 Tyrosine Kinase Domain (TKD) Mutation Profiles in a Xenograft Model of FLT3-ITD+ Acute Myeloid Leukemia (AML). <i>Blood</i> , 2014 , 124, 3620-3620	2.2	
7	Genomic Profiling Identifies Novel Mutations and Fusion Genes in Newly Diagnosed and Relapsed Pediatric FLT3-ITD-Positive AML. <i>Blood</i> , 2016 , 128, 2838-2838	2.2	
6	Gene Expression Profiling of Acute Myeloid Leukemia Shows Therapeutically Meaningful Patterns of Association with Ara-CTP Pharmacokinetics and Pharmacodynamics. <i>Blood</i> , 2008 , 112, 215-215	2.2	
5	Microenvironmental Factors Determine the Sensitivity of Acute Myeloid Leukemia Cells to Tyrosine Kinase Inhibitors.. <i>Blood</i> , 2008 , 112, 1630-1630	2.2	
4	Inhibition of Class I PI3K Isoforms Restores the Sensitivity of Acute Myelogenous Leukemia Cells to Multi-Tyrosine Kinase Inhibitors in the Bone Marrow Microenvironment.. <i>Blood</i> , 2009 , 114, 1734-1734	2.2	
3	Recommendation of dose banding of cytotoxics according to pharmacokinetic criteria.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2549-2549	2.2	
2	TAK1 is a Regulator of Sorafenib-induced Keratinocyte Toxicity. <i>FASEB Journal</i> , 2013 , 27, 657.1	0.9	

- 1 Genetic variations in cytarabine pathway genes as determinants of outcome in acute myeloid leukemia.. *Journal of Clinical Oncology*, **2013**, 31, 10005-10005 2.2